Mesoblast wins Japanese patent for stem cell platform
Mesoblast (ASX:MSB) has picked up a Japanese patent covering its Mesenchymal Precursor Cell (MPC) adult stem cell platform.
The patent grants Mesoblast exclusive commercial rights to all compositions of matter and uses of the platform in the Japanese market.
The protection, which applies regardless of the stem cell tissue source, will be valid through to September 2025.
Mesoblast also recently secured two Chinese patents covering its MPC platform - which also expire in 2029 - and an extension of its US composition-of-matter patents until March 2029.
The company is using its MPC platform to develop off-the-shelf regenerative medicine products. Lead targets include rheumatoid arthritis, congestive heart failure and orthopaedic conditions including spinal fusion.
The granting of the patent comes weeks after fellow Australian biotech BioDiem (ASX:BDM) won its own Japanese patent covering antimicrobial compound BDM-I.
Mesoblast shares were trading 0.16% lower at $6.15 as of around 1.30 pm on Wednesday.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
